NS1738 | CAS#501684-93-1 |α7 Positive Modulator

MedKoo Cat#: 532365 | Name: NS1738

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NS1738 is a α7 positive allosteric modulator.

Chemical Structure

NS1738

CAS#501684-93-1

Theoretical Analysis

MedKoo Cat#: 532365

Name: NS1738

CAS#: 501684-93-1

Chemical Formula: C14H9Cl2F3N2O2

Exact Mass: 363.9993

Molecular Weight: 365.13

Elemental Analysis: C, 46.05; H, 2.48; Cl, 19.42; F, 15.61; N, 7.67; O, 8.76

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 240.00
10mg	USD 360.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

NS1738; NS 1738; NS-1738.

IUPAC/Chemical Name

3-(5-chloro-2-hydroxyphenyl)-1-[2-chloro-5-(trifluoromethyl)phenyl]urea

InChi Key

OUDXRNQPVSMGDW-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H9Cl2F3N2O2/c15-8-2-4-12(22)11(6-8)21-13(23)20-10-5-7(14(17,18)19)1-3-9(10)16/h1-6,22H,(H2,20,21,23)

SMILES Code

O=C(NC1=CC(Cl)=CC=C1O)NC2=CC(C(F)(F)F)=CC=C2Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

NS 1738 (NSC 213859) is a novel positive allosteric modulator of the α7 nAChR.

In vitro activity:

This strategy revealed that the extracellular N-terminal domain of alpha7 plays a critical role in allosteric modulation by NS-1738. In addition, alpha7-5HT(3) chimeras harboring the M2-M3 segment showed that spontaneous activity in response to NS-1738, which confirmed the critical contribution of this small extracellular segment in the receptor gating. In contrast to NS-1738, positive allosteric modulation by PNU-120596 could not be restored in the alpha7-5HT(3) chimeras but was selectively observed in the reverse 5HT(3)-alpha7 chimera. Reference: Mol Pharmacol. 2008 Nov;74(5):1407-16. https://pubmed.ncbi.nlm.nih.gov/18678621/

In vivo activity:

NS1738 was modestly brain-penetrant, and it was demonstrated to counteract a (-)-scopolamine-induced deficit in acquisition of a water-maze learning task in rats. Moreover, NS1738 improved performance in the rat social recognition test to the same extent as (-)-nicotine, demonstrating that NS1738 is capable of producing cognitive enhancement in vivo. Reference: J Pharmacol Exp Ther. 2007 Oct;323(1):294-307. https://pubmed.ncbi.nlm.nih.gov/17625074/

	Solvent	mg/mL	mM
Solubility
	DMF	25.0	68.47
	DMSO	58.6	160.56
	DMSO:PBS (pH 7.2) (1:3)	0.3	0.68
	Ethanol	39.8	109.10

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 365.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Bertrand D, Bertrand S, Cassar S, Gubbins E, Li J, Gopalakrishnan M. Positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor: ligand interactions with distinct binding sites and evidence for a prominent role of the M2-M3 segment. Mol Pharmacol. 2008 Nov;74(5):1407-16. doi: 10.1124/mol.107.042820. Epub 2008 Aug 4. PMID: 18678621. 2. Timmermann DB, Grønlien JH, Kohlhaas KL, Nielsen EØ, Dam E, Jørgensen TD, Ahring PK, Peters D, Holst D, Christensen JK, Malysz J, Briggs CA, Gopalakrishnan M, Olsen GM. An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther. 2007 Oct;323(1):294-307. doi: 10.1124/jpet.107.120436. Epub 2007 Jul 11. Erratum in: J Pharmacol Exp Ther. 2009 Dec;331(3):1146. Chrsitensen, Jeppe K [corrected to Christensen, Jeppe K]. PMID: 17625074. 3. 1. Freitas K, Carroll FI, Damaj MI. The antinociceptive effects of nicotinic receptors α7-positive allosteric modulators in murine acute and tonic pain models. J Pharmacol Exp Ther. 2013 Jan;344(1):264-75. doi: 10.1124/jpet.112.197871. Epub 2012 Oct 31. PMID: 23115222; PMCID: PMC3533419.

In vitro protocol:

In vivo protocol:

1. Freitas K, Carroll FI, Damaj MI. The antinociceptive effects of nicotinic receptors α7-positive allosteric modulators in murine acute and tonic pain models. J Pharmacol Exp Ther. 2013 Jan;344(1):264-75. doi: 10.1124/jpet.112.197871. Epub 2012 Oct 31. PMID: 23115222; PMCID: PMC3533419. 2. Timmermann DB, Grønlien JH, Kohlhaas KL, Nielsen EØ, Dam E, Jørgensen TD, Ahring PK, Peters D, Holst D, Christensen JK, Malysz J, Briggs CA, Gopalakrishnan M, Olsen GM. An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther. 2007 Oct;323(1):294-307. doi: 10.1124/jpet.107.120436. Epub 2007 Jul 11. Erratum in: J Pharmacol Exp Ther. 2009 Dec;331(3):1146. Chrsitensen, Jeppe K [corrected to Christensen, Jeppe K]. PMID: 17625074.

1: Cheng Q, Yakel JL. Presynaptic α7 nicotinic acetylcholine receptors enhance hippocampal mossy fiber glutamatergic transmission via PKA activation. J Neurosci. 2014 Jan 1;34(1):124-33. doi: 10.1523/JNEUROSCI.2973-13.2014. PubMed PMID: 24381273; PubMed Central PMCID: PMC3866480. 2: Freitas K, Ghosh S, Ivy Carroll F, Lichtman AH, Imad Damaj M. Effects of α7 positive allosteric modulators in murine inflammatory and chronic neuropathic pain models. Neuropharmacology. 2013 Feb;65:156-64. doi: 10.1016/j.neuropharm.2012.08.022. Epub 2012 Oct 16. PubMed PMID: 23079470; PubMed Central PMCID: PMC3521074.